Analytical Data
-
Gene name
CCNK
- Application
-
Alternative Names
CPR4; CyclinK
-
Species
Human
-
Source
Baculovirus
-
Tag
GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75909-3
-
Expression Region
M1-R580
-
Protein Length
Full Length of Isoform-3
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNK (cyclin C-related kinase) is a member of the cyclin-dependent kinase (CDK) family, which plays a crucial role in cell cycle regulation and transcription. Recent research highlights the importance of CCNK in various cellular processes, including its potential involvement in oncogenesis. The protein exhibits unique interactions with cyclins and substrate proteins, suggesting a complex regulatory mechanism in cell proliferation and differentiation. Studies have shown that alterations in CCNK expression levels can lead to abnormal cell cycle progression and are associated with certain cancers. Consequently, the investigation of CCNK as a therapeutic target has garnered significant interest. Researchers are exploring the structural and functional aspects of CCNK to develop specific inhibitors that could modulate its activity, providing a possible avenue for cancer treatment. Furthermore, the recombinant expression of CCNK allows for detailed characterization of its biochemical properties and interactions within the cell, ultimately contributing to a better understanding of its role in cancer biology. This background sets the stage for future studies aimed at elucidating the precise functions of CCNK and its potential as a biomarker or therapeutic target in malignancies.
